Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08, Briefing.com reports. Endologix had a negative return on equity of 44.60% and a negative net margin of 40.77%. The company had revenue of $48.60 million during the quarter, compared to analyst estimates of $47.58 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. Endologix’s revenue was down 4.6% compared to the same quarter last year.

Endologix (ELGX) traded down 4.023% during trading on Friday, reaching $4.175. The company had a trading volume of 2,017,564 shares. Endologix has a 52 week low of $4.17 and a 52 week high of $13.30. The firm’s market capitalization is $348.30 million. The stock has a 50 day moving average price of $4.91 and a 200 day moving average price of $6.07.

Several brokerages recently commented on ELGX. Canaccord Genuity reaffirmed a “hold” rating on shares of Endologix in a report on Friday. Oppenheimer Holdings, Inc. set a $5.00 target price on Endologix and gave the company a “hold” rating in a research report on Thursday. Stifel Nicolaus set a $6.00 target price on Endologix and gave the company a “hold” rating in a research report on Wednesday. Royal Bank Of Canada reiterated a “hold” rating and set a $5.00 target price on shares of Endologix in a research report on Monday. Finally, Zacks Investment Research downgraded Endologix from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Eleven equities research analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and an average price target of $6.28.

TRADEMARK VIOLATION NOTICE: “Endologix, Inc. (NASDAQ:ELGX) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/04/endologix-inc-nasdaqelgx-releases-quarterly-earnings-results-beats-expectations-by-0-08-eps.html.

In related news, Director Guido J. Neels purchased 20,000 shares of the business’s stock in a transaction on Friday, May 19th. The shares were bought at an average cost of $4.32 per share, with a total value of $86,400.00. Following the transaction, the director now owns 61,380 shares of the company’s stock, valued at $265,161.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dan Lemaitre purchased 22,522 shares of the business’s stock in a transaction on Monday, May 22nd. The shares were bought at an average cost of $4.43 per share, for a total transaction of $99,772.46. Following the completion of the transaction, the director now directly owns 68,689 shares in the company, valued at approximately $304,292.27. The disclosure for this purchase can be found here. Insiders have acquired a total of 44,722 shares of company stock worth $195,676 over the last ninety days. 3.90% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the company. C WorldWide Group Holding A S boosted its stake in Endologix by 41.8% in the first quarter. C WorldWide Group Holding A S now owns 524,556 shares of the medical instruments supplier’s stock worth $3,798,000 after buying an additional 154,556 shares during the period. Stoneridge Investment Partners LLC boosted its stake in Endologix by 142.4% in the first quarter. Stoneridge Investment Partners LLC now owns 196,344 shares of the medical instruments supplier’s stock worth $1,422,000 after buying an additional 115,337 shares during the period. Great West Life Assurance Co. Can boosted its stake in Endologix by 6,604.0% in the first quarter. Great West Life Assurance Co. Can now owns 448,025 shares of the medical instruments supplier’s stock worth $3,249,000 after buying an additional 441,342 shares during the period. Wells Fargo & Company MN boosted its stake in Endologix by 7.6% in the first quarter. Wells Fargo & Company MN now owns 157,990 shares of the medical instruments supplier’s stock worth $1,144,000 after buying an additional 11,188 shares during the period. Finally, Emerald Advisers Inc. PA acquired a new stake in Endologix during the first quarter worth approximately $222,000.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Earnings History for Endologix (NASDAQ:ELGX)

Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.